Qualigen Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
AIxCrypto Holdings, Inc. announces its 2024 Annual Meeting for December 2025, detailing director elections, executive compensation, and auditor changes amidst continued net losses.
Qualigen Therapeutics, Inc. is convening a Special Meeting on November 12, 2025, to seek stockholder approval for a $41 million private placement, a new equity incentive plan, and related share issuances.
Qualigen Therapeutics supplements its proxy statement, providing updated information on director nominees for the upcoming annual meeting on October 25, 2024.
Qualigen Therapeutics is holding its 2024 Annual Meeting of Stockholders on October 25, 2024, to vote on key proposals including a reverse stock split, director elections, and ratification of the company's independent accounting firm.